The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C

Ned Snyder, Audrey Nguyen, Leka Gajula, Roger Soloway, Shu Yuan Xiao, Daryl T Y Lau, John Petersen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Multiple serum markers to estimate hepatic fibrosis in chronic liver disease have been proposed. The AST/Platelet Ratio Index (APRI) is a simple biochemical index that has been shown to be useful and accurate in about 50% of patients with chronic hepatitis C. We determined if the combination of the APRI and the FIBROSpect II, a commercially available hepatic fibrosis marker that measures 3 components of the extracellular hepatic matrix, would further help distinguish mild from significant fibrosis in a group of patients with chronic hepatitis C. Methods: In an outpatient setting, 93 consecutive patients were studied who were undergoing staging liver biopsy for chronic hepatitis C who had a liver biopsy length ≥ 1.5 cm. All had blood drawn at the time of the biopsy. Liver biopsies were staged for fibrosis by the Batts Ludwig criteria (F0-F4). Patients with previous anti-viral therapy, hepatocellular carcinoma, an organ transplant, or co-infection with HIV or hepatitis B were excluded. The APRI was calculated and FIBROSpect II determined. Results: The AUC of the ROC curve for the APRI and FIBROSpect II were 0.887 and 0.879 respectively. Using cutoffs of ≤ 0.42 for mild fibrosis (F0-F1) and ≥ 1.2 for significant fibrosis, the APRI correctly estimated 19 of 20 patients with mild fibrosis for an NPV of 95.0%, and 31 of 33 patients with significant fibrosis for a PPV of 93.6%. The FIBROSpect II also works best utilizing 2 cutoffs, and using cutoffs of ≤ 25 and ≥ 85 it correctly identified 18 of 18 patients with mild fibrosis and all 26 patients with significant fibrosis for an NPV and PPV of 100% for both. Among the 40 patients who could not be classified by the APRI, an additional 16 could be correctly classified using the FIBROSpect II with cutoffs of ≤ 25 and ≥ 85. This lowered the indeterminate zone from 43.0 to 25.8%. By combining the APRI and the FIBROSpect II, the AUC for the ROC curve improved significantly to 0.931 (p = 0.013). Conclusions: The APRI and the FIBROSpect II are both accurate tests for separating mild from significant fibrosis. By using the APRI as the initial screen, > 50% of patients with mild or significant fibrosis can be correctly identified. If the patient falls in the indeterminate zone, then the more expensive FIBROSpect II could be obtained. This strategy could decrease the number of liver biopsies.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalClinica Chimica Acta
Volume381
Issue number2
DOIs
StatePublished - Jun 2007

Fingerprint

Chronic Hepatitis C
Platelets
Fibrosis
Blood Platelets
Biopsy
Liver
ROC Curve
Area Under Curve
Transplants
Blood
Hepatitis B
Coinfection
Extracellular Matrix
Liver Diseases
Hepatocellular Carcinoma
Chronic Disease
Outpatients
Biomarkers
HIV

Keywords

  • Aspartate aminotransferase
  • Fibrosis
  • Hepatitis C
  • Platelets

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Snyder, N., Nguyen, A., Gajula, L., Soloway, R., Xiao, S. Y., Lau, D. T. Y., & Petersen, J. (2007). The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clinica Chimica Acta, 381(2), 119-123. https://doi.org/10.1016/j.cca.2007.02.046

The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. / Snyder, Ned; Nguyen, Audrey; Gajula, Leka; Soloway, Roger; Xiao, Shu Yuan; Lau, Daryl T Y; Petersen, John.

In: Clinica Chimica Acta, Vol. 381, No. 2, 06.2007, p. 119-123.

Research output: Contribution to journalArticle

Snyder, N, Nguyen, A, Gajula, L, Soloway, R, Xiao, SY, Lau, DTY & Petersen, J 2007, 'The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C', Clinica Chimica Acta, vol. 381, no. 2, pp. 119-123. https://doi.org/10.1016/j.cca.2007.02.046
Snyder, Ned ; Nguyen, Audrey ; Gajula, Leka ; Soloway, Roger ; Xiao, Shu Yuan ; Lau, Daryl T Y ; Petersen, John. / The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. In: Clinica Chimica Acta. 2007 ; Vol. 381, No. 2. pp. 119-123.
@article{c698ea3bebd84983a0701be637f80f5d,
title = "The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C",
abstract = "Background: Multiple serum markers to estimate hepatic fibrosis in chronic liver disease have been proposed. The AST/Platelet Ratio Index (APRI) is a simple biochemical index that has been shown to be useful and accurate in about 50{\%} of patients with chronic hepatitis C. We determined if the combination of the APRI and the FIBROSpect II, a commercially available hepatic fibrosis marker that measures 3 components of the extracellular hepatic matrix, would further help distinguish mild from significant fibrosis in a group of patients with chronic hepatitis C. Methods: In an outpatient setting, 93 consecutive patients were studied who were undergoing staging liver biopsy for chronic hepatitis C who had a liver biopsy length ≥ 1.5 cm. All had blood drawn at the time of the biopsy. Liver biopsies were staged for fibrosis by the Batts Ludwig criteria (F0-F4). Patients with previous anti-viral therapy, hepatocellular carcinoma, an organ transplant, or co-infection with HIV or hepatitis B were excluded. The APRI was calculated and FIBROSpect II determined. Results: The AUC of the ROC curve for the APRI and FIBROSpect II were 0.887 and 0.879 respectively. Using cutoffs of ≤ 0.42 for mild fibrosis (F0-F1) and ≥ 1.2 for significant fibrosis, the APRI correctly estimated 19 of 20 patients with mild fibrosis for an NPV of 95.0{\%}, and 31 of 33 patients with significant fibrosis for a PPV of 93.6{\%}. The FIBROSpect II also works best utilizing 2 cutoffs, and using cutoffs of ≤ 25 and ≥ 85 it correctly identified 18 of 18 patients with mild fibrosis and all 26 patients with significant fibrosis for an NPV and PPV of 100{\%} for both. Among the 40 patients who could not be classified by the APRI, an additional 16 could be correctly classified using the FIBROSpect II with cutoffs of ≤ 25 and ≥ 85. This lowered the indeterminate zone from 43.0 to 25.8{\%}. By combining the APRI and the FIBROSpect II, the AUC for the ROC curve improved significantly to 0.931 (p = 0.013). Conclusions: The APRI and the FIBROSpect II are both accurate tests for separating mild from significant fibrosis. By using the APRI as the initial screen, > 50{\%} of patients with mild or significant fibrosis can be correctly identified. If the patient falls in the indeterminate zone, then the more expensive FIBROSpect II could be obtained. This strategy could decrease the number of liver biopsies.",
keywords = "Aspartate aminotransferase, Fibrosis, Hepatitis C, Platelets",
author = "Ned Snyder and Audrey Nguyen and Leka Gajula and Roger Soloway and Xiao, {Shu Yuan} and Lau, {Daryl T Y} and John Petersen",
year = "2007",
month = "6",
doi = "10.1016/j.cca.2007.02.046",
language = "English (US)",
volume = "381",
pages = "119--123",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C

AU - Snyder, Ned

AU - Nguyen, Audrey

AU - Gajula, Leka

AU - Soloway, Roger

AU - Xiao, Shu Yuan

AU - Lau, Daryl T Y

AU - Petersen, John

PY - 2007/6

Y1 - 2007/6

N2 - Background: Multiple serum markers to estimate hepatic fibrosis in chronic liver disease have been proposed. The AST/Platelet Ratio Index (APRI) is a simple biochemical index that has been shown to be useful and accurate in about 50% of patients with chronic hepatitis C. We determined if the combination of the APRI and the FIBROSpect II, a commercially available hepatic fibrosis marker that measures 3 components of the extracellular hepatic matrix, would further help distinguish mild from significant fibrosis in a group of patients with chronic hepatitis C. Methods: In an outpatient setting, 93 consecutive patients were studied who were undergoing staging liver biopsy for chronic hepatitis C who had a liver biopsy length ≥ 1.5 cm. All had blood drawn at the time of the biopsy. Liver biopsies were staged for fibrosis by the Batts Ludwig criteria (F0-F4). Patients with previous anti-viral therapy, hepatocellular carcinoma, an organ transplant, or co-infection with HIV or hepatitis B were excluded. The APRI was calculated and FIBROSpect II determined. Results: The AUC of the ROC curve for the APRI and FIBROSpect II were 0.887 and 0.879 respectively. Using cutoffs of ≤ 0.42 for mild fibrosis (F0-F1) and ≥ 1.2 for significant fibrosis, the APRI correctly estimated 19 of 20 patients with mild fibrosis for an NPV of 95.0%, and 31 of 33 patients with significant fibrosis for a PPV of 93.6%. The FIBROSpect II also works best utilizing 2 cutoffs, and using cutoffs of ≤ 25 and ≥ 85 it correctly identified 18 of 18 patients with mild fibrosis and all 26 patients with significant fibrosis for an NPV and PPV of 100% for both. Among the 40 patients who could not be classified by the APRI, an additional 16 could be correctly classified using the FIBROSpect II with cutoffs of ≤ 25 and ≥ 85. This lowered the indeterminate zone from 43.0 to 25.8%. By combining the APRI and the FIBROSpect II, the AUC for the ROC curve improved significantly to 0.931 (p = 0.013). Conclusions: The APRI and the FIBROSpect II are both accurate tests for separating mild from significant fibrosis. By using the APRI as the initial screen, > 50% of patients with mild or significant fibrosis can be correctly identified. If the patient falls in the indeterminate zone, then the more expensive FIBROSpect II could be obtained. This strategy could decrease the number of liver biopsies.

AB - Background: Multiple serum markers to estimate hepatic fibrosis in chronic liver disease have been proposed. The AST/Platelet Ratio Index (APRI) is a simple biochemical index that has been shown to be useful and accurate in about 50% of patients with chronic hepatitis C. We determined if the combination of the APRI and the FIBROSpect II, a commercially available hepatic fibrosis marker that measures 3 components of the extracellular hepatic matrix, would further help distinguish mild from significant fibrosis in a group of patients with chronic hepatitis C. Methods: In an outpatient setting, 93 consecutive patients were studied who were undergoing staging liver biopsy for chronic hepatitis C who had a liver biopsy length ≥ 1.5 cm. All had blood drawn at the time of the biopsy. Liver biopsies were staged for fibrosis by the Batts Ludwig criteria (F0-F4). Patients with previous anti-viral therapy, hepatocellular carcinoma, an organ transplant, or co-infection with HIV or hepatitis B were excluded. The APRI was calculated and FIBROSpect II determined. Results: The AUC of the ROC curve for the APRI and FIBROSpect II were 0.887 and 0.879 respectively. Using cutoffs of ≤ 0.42 for mild fibrosis (F0-F1) and ≥ 1.2 for significant fibrosis, the APRI correctly estimated 19 of 20 patients with mild fibrosis for an NPV of 95.0%, and 31 of 33 patients with significant fibrosis for a PPV of 93.6%. The FIBROSpect II also works best utilizing 2 cutoffs, and using cutoffs of ≤ 25 and ≥ 85 it correctly identified 18 of 18 patients with mild fibrosis and all 26 patients with significant fibrosis for an NPV and PPV of 100% for both. Among the 40 patients who could not be classified by the APRI, an additional 16 could be correctly classified using the FIBROSpect II with cutoffs of ≤ 25 and ≥ 85. This lowered the indeterminate zone from 43.0 to 25.8%. By combining the APRI and the FIBROSpect II, the AUC for the ROC curve improved significantly to 0.931 (p = 0.013). Conclusions: The APRI and the FIBROSpect II are both accurate tests for separating mild from significant fibrosis. By using the APRI as the initial screen, > 50% of patients with mild or significant fibrosis can be correctly identified. If the patient falls in the indeterminate zone, then the more expensive FIBROSpect II could be obtained. This strategy could decrease the number of liver biopsies.

KW - Aspartate aminotransferase

KW - Fibrosis

KW - Hepatitis C

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=34248231382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248231382&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2007.02.046

DO - 10.1016/j.cca.2007.02.046

M3 - Article

C2 - 17442291

AN - SCOPUS:34248231382

VL - 381

SP - 119

EP - 123

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 2

ER -